INTRODUCTION
============

Gastrostomy feeding is recommended for patients with dysphagia to improve nutrition.[@B1] Previously, gastrostomy tubes were placed solely using the open surgical technique. However, percutaneous endoscopic gastrostomy (PEG) has replaced surgical placement since it was introduced by Gauderer and Ponsky in 1980.[@B2] Radiologically-inserted gastrostomy (RIG) was also introduced in 1981 and has been used as an alternative to PEG for enteral feeding with a high rate of technical success under local anesthesia.[@B3] Although PEG and RIG are both considered minimally invasive, they are associated with considerable early mortality (30-day mortality), which has been reported as 5.8% to 28% for PEG and 1% to 40% for RIG.[@B4][@B5][@B6][@B7][@B8][@B9] Furthermore, various complications such as wound infections, hemorrhage, hematoma formation, aspiration pneumonia, or gastric perforation may develop after gastrostomy. Although pneumoperitoneum is a complication which is usually considered minor, a previous study reported mortality related to pneumoperitoneum after PEG insertion.[@B10] Considering that less invasive alternatives do exist, such as a nasogastric tube insertion for short-term tube feeding, it is important to evaluate the safety of gastrostomy. Thirty-day mortality is one of the most important surrogate indices for evaluating the safety of percutaneous gastrostomy.[@B1][@B11][@B12] However, no systematic reviews or meta-analyses have compared PEG and RIG in terms of 30-day mortality rates. In the absence of sufficient evidence, the choice between PEG and RIG is largely based on expert opinions or institutional preference. The aim of the present study was to perform a systemic review and meta-analysis comparing the 30-day mortality rates after PEG and RIG.

METHODS
=======

The protocol for this review was developed prospectively. The checklist and flow chart of the preferred reporting items for systematic review and meta-analyses (PRISMA) statement were used for the review process and data extraction.[@B13] We prepared a prespecified protocol of the specific patients (patients with dysphagia), interventions (PEG), controls (RIG), the primary outcome (the 30-day mortality), the criteria for study selection, and the assessment of study quality.

1. Search Strategy
------------------

To identify all available studies, a detailed search was conducted according to the PRISMA guidelines.[@B12] A systematic search was performed in major electronic databases (MEDLINE, Cochrane library, Scopus, and Embase) using the following search terms: \"Gastrostomy\" AND \"Endoscopic\" AND \"Radiologic^\*^\". The search was restricted to literature from January 1980 to May 2015. Non-English or non-Korean language trials were translated and included.

2. Study Selection
------------------

The following selection criteria were applied: (1) patients with dysphagia or in need of prolonged tube feeding; (2) randomized controlled trials (RCT) or other comparative studies comparing 30-day mortality between PEG and RIG; (3) outcome measures of 30-day mortality; and (4) studies that were published in peer-reviewed journals. As there have been only two randomized control trials comparing PEG versus RIG to date, this analysis included both prospective and retrospective comparative studies.

Studies were excluded when they met any of the following criteria: (1) preclinical studies, case reports, case series, or review articles; (2) studies with RIG placement after failure of PEG; (3) studies with no data pertaining to 30-day mortality rates; or (4) studies with no cases of 30-day mortality in either the PEG and the RIG group or duplicated reports from the same patient.

The results of the database search were imported into EndNote X7 software (Thomson Reuters, Philadelphia, PA, USA) and combined into one group to remove duplicated references. Two authors (J.H.L. and S.H.C.) independently assessed the titles and abstracts of all the studies identified by the search. Full texts of potentially eligible articles were obtained and reviewed to assess whether the studies fulfilled the inclusion criteria. Any disagreements between reviewers were resolved through discussion. When an agreement was not achieved, another author (C.L.) was consulted.

3. Quality Assessment
---------------------

The quality of the RCTs was assessed using the Jadad scale.[@B14] The quality and risk of bias of nonrandomized comparative studies (NRCT) was assessed using the methodological index for nonrandomized studies (MINORS).[@B15]

4. Data Extraction
------------------

Two independent authors (J.H.L. and S.H.C.) analyzed each article and extracted data using a predefined data extraction worksheet. The following information was extracted from each article: title, first author, year of publication, country of origin, study design, patient demographics, the interventions being compared, number of patients, and the 30-day mortality rate.

5. Statistical Analysis and Publication Bias Assessment
-------------------------------------------------------

A meta-analysis was carried out using STATA version 14 (Stata Corp, Texas, TX, USA). We used the STATA metan command for fixed-model (Mantel-Haenszel) analysis and random-effect (DerSimonian and Laird) analysis. We excluded trials with no cases of 30-day mortality in either intervention groups. Differences between the PEG and RIG groups were expressed as the pooled OR with 95% CI. We also used the STATA metan command to create a forest plot and calculate the pooled prevalence. Publication bias was presented graphically by funnel plots of the standard difference in means versus the standard error using the \"metafunnel\" command and assessed by the Egger\'s test using the \"metabias\" command. Subgroup analysis was performed in each group of patients with motor neuron disease and head and neck cancer.

RESULTS
=======

1. Search Results
-----------------

According to the PRISMA flowchart, the selection results are reported in [Fig. 1](#F1){ref-type="fig"}.[@B13] We identified 828 citations through the electronic database search, and 445 citations remained after duplicates were removed. Initial screening of the titles and abstracts resulted in the exclusion of 414 citations, and full texts of the remaining 31 citations were reviewed in detail.[@B8][@B9][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29][@B30][@B31][@B32][@B33][@B34][@B35][@B36][@B37][@B38][@B39][@B40][@B41][@B42][@B43][@B44] An additional 16 citations were excluded after reviewing the full articles, for the following reasons: duplicated reports,[@B42][@B43][@B44] noncomparative studies,[@B37] studies with RIG placement after failure of PEG,[@B25][@B35] no data present on 30-day mortality,[@B29][@B40][@B41] no reported case of 30-day mortality,[@B19][@B27][@B30][@B34][@B36][@B38] and review articles.[@B17][@B21] Fifteen published studies including two RCTs[@B16][@B39] and 13 NRCTs[@B8][@B9][@B19][@B20][@B22][@B23][@B24][@B26][@B28][@B31][@B32][@B33][@B42] were included in the final analysis.

2. Baseline Characteristics of the Included Studies
---------------------------------------------------

A total of 1,135 patients with PEG insertion and 1,048 patients with RIG insertion were included in the 15 studies. Blinding was not applied to the two RCTs, and the Jadad scores of the two studies were 2 and 3. The quality of the NRCTs was measured by the MINORS score, and the estimated mean MINORS score was 18.6 (95% CI, 17.27-19.95). The characteristics of these studies and quality assessment scores are detailed in [Table 1](#T1){ref-type="table"}. These studies were published from 1997 to 2015. All of the studies were performed in Western countries (six in the UK, four in the USA, two in France, and one in Australia, Canada, and New Zealand, each). The underlying diseases of the patients varied (mixed in eight studies, motor neuron disease in five studies, head and neck cancer in two studies), and the sample sizes of the studies ranged from 43 to 403 patients. Detailed indications are presented in [Table 2](#T2){ref-type="table"}.

3. The 30-Day Mortality Rate Following PEG versus RIG
-----------------------------------------------------

The 30-day mortality rates reported by each study are shown in [Table 3](#T3){ref-type="table"} and [Fig. 2A](#F2){ref-type="fig"}. A pooled analysis of the two RCTs with the fixed model showed no difference between the two groups (OR, 1.18; 95% CI, 0.38-3.66; *P*=0.770). As this result was thought to be due to the small number of RCTs included, we performed a pooled analysis with RCTs and NRCTs combined. The pooled analysis of the ORs demonstrated a statistically significant reduction of 30-day mortality rates in the PEG groups compared with the RIG groups (OR, 0.60; 95% CI, 0.44-0.82; *P*=0.001) ([Fig. 2A](#F2){ref-type="fig"}) in a fixed effects model with moderate heterogeneity (heterogeneity χ^2^=22.68, I^2^=38.7%, *P*=0.063). Because of this moderate heterogeneity, we next used a random effects model to perform a pooled analysis of the ORs. In the random effects model, the pooled analysis of the ORs also demonstrated a statistically significant reduction of 30-day mortality rates in the PEG groups (OR, 0.60; 95% CI, 0.38-0.94; *P*=0.026) ([Fig. 2B](#F2){ref-type="fig"}). The funnel plot assay ([Fig. 3](#F3){ref-type="fig"}) and the Egger\'s test (*P*=0.542) did not show evidence of publication bias.

Next, we calculated the pooled 30-day mortality rate in the PEG and RIG groups. The pooled prevalence of 30-day mortality of the PEG group was 5.5% (95% CI, 4.0%-6.9%) in a fixed effects model with low heterogeneity (heterogeneity χ^2^=17.09, I^2^=18.1%, *P*=0.251). The pooled prevalence of 30-day mortality of the RIG group was 6.7% (95% CI, 5.1%-8.3%) in a fixed effects model with high heterogeneity (heterogeneity χ^2^=50.92, I^2^=72.5%, *P*\<0.001). Because of this high heterogeneity, we then applied a random effects model. In the random effects model, the pooled prevalence of 30-day mortality of the RIG group was 10.5% (95% CI, 6.8%-14.3%).

4. The 30-Day Mortality Rate Following PEG versus RIG in Patients with Motor Neuron Disease
-------------------------------------------------------------------------------------------

A total of five studies[@B9][@B19][@B22][@B24][@B32] were performed in patients with motor neuron disease. Pooled analysis of the ORs showed no significant difference in 30-day mortality between the PEG group and RIG group (OR, 0.84; 95% CI, 0.43-1.69; *P*=0.637) ([Fig. 4A](#F4){ref-type="fig"}) with low heterogeneity (heterogeneity χ^2^=0.71, I^2^\<0.1%, *P*=0.950). The funnel plot assay ([Fig. 4B](#F4){ref-type="fig"}) and the Egger\'s test (*P*=0.124) did not show evidence of publication bias.

5. The 30-Day Mortality Rate Following PEG versus RIG in Patients with Head and Neck Cancer
-------------------------------------------------------------------------------------------

A total of three studies[@B23][@B28][@B33] were performed in patients with head and neck cancer including a subgroup analysis study.[@B23] The pooled OR of 30-day mortality was significantly reduced in the PEG group compared to the RIG group (OR, 0.09; 95% CI, 0.03-0.28; *P*\<0.001) ([Fig. 5A](#F5){ref-type="fig"}) with low heterogeneity (heterogeneity χ^2^=0.51, I^2^\<0.1%, *P*=0.775). The funnel plot assay ([Fig. 5B](#F5){ref-type="fig"}) and the Egger\'s test (*P*=0.060) did not show evidence of publication bias.

DISCUSSION
==========

This is the first systematic review and meta-analysis comparing the 30-day mortality rates of PEG versus RIG. We reviewed 30-day mortality after PEG or RIG by summarizing 15 peer-reviewed studies, including 1,135 patients who underwent PEG and 1,048 patients who underwent RIG. A significantly lower risk of 30-day morality was found in the PEG group compared to that in the RIG group (OR, 0.60; 95% CI, 0.38-0.94; *P*=0.026). This finding supports the current trend of clinical practice, in which PEG is the method of choice for long-term enteral tube feeding, and RIG is an alternative method with a high rate of technical success for those who refuse endoscopy or are unsuitable for PEG.

PEG and RIG placement are generally known as safe and feasible procedures with low mortality rates.[@B9] In this meta-analysis, the pooled 30-day mortality rate of the PEG group was 5.5% (95% 4.0%-6.9%) and that of the RIG group was 10.5% (95% CI, 6.8%-14.3%). These findings suggest that more careful exploration of the risks and benefits of the procedure is needed, especially for RIG, because less invasive methods exist for short-term tube feeding, such as nasogastric tube insertion.

The reason for the lower 30-day mortality rate in the PEG group could be due to the following: first, administration of prophylactic antibiotics is recommended in PEG and is not generally recommended in RIG,[@B45] which may have resulted in a reduction in the rates of peristomal infection and other acute infectious complications in PEG;[@B8][@B9][@B31][@B33] second, the tubes used in the two methods differ in shape, as the RIG tubes are relatively thinner in diameter (10-14 F) than the PEG tubes (20 F), and clogging of the feeding tube or tube blockage would be more frequent in tubes of smaller diameters; [@B1] furthermore, as RIG tubes are fixed with a balloonretention system, they are not as securely fixed as PEG tubes, and peristomal leakage or tube displacement would be more frequent.[@B28][@B33] These differences in tubes may have induced a significant increase in the rate of tube related complications.[@B9] Furthermore, there were differences in underlying diseases between the two groups. The PEG group contained more patients with neurological impairment, while the RIG group included more patients with head and neck cancer. These differences might have influenced the outcomes of the study.

In a subgroup analysis of patients with motor neuron disease, the 30-day mortality rates of the PEG and RIG groups were not significantly different. The PEG procedure in patients with motor neuron disease was generally considered more risky due to probable respiratory distress.[@B24] However, our results provide evidence that PEG is not inferior to RIG in these patients.

The subgroup analysis of patients with head and neck cancer demonstrated a statistically significant reduction in the 30-day mortality rate of the PEG group compared to that of RIG group. In general, a radiological approach is preferred in patients with head and neck cancer because of concerns about tumor seeding and technical problems with oral insertion due to the location of the tumor. However, only three studies were conducted in patients with head and neck cancer to compare 30-day mortality in PEG versus RIG; the small study effect demonstrated by the Egger\'s test was not significant (*P*=0.06). Considering these results, PEG is thought to be a safe method for gastrostomy even in patients with head and neck cancer.

There are several limitations to this study. First, most studies enrolled in this meta-analysis were observational studies without randomization of insertion methods, and all the groups were not matched exactly. Although gastrostomy has been widely used, there is a lack of randomized trials on this issue. Because of difficult ethical problems surrounding feeding and the issues of vulnerability in patients with impaired neurology, large randomized controlled studies are not easily performed and are less motivating in changing clinical practice.[@B46] Although many researchers argue that combining analyses of RCTs and NRCTs in a meta-analysis should be avoided, both study designs contain strengths and weaknesses in principle. Additionally, including results from observational studies has been suggested as a means of improving the inferences made only by RCTs. We searched peer-reviewed articles only, and excluded biased studies. Therefore, we believe that this meta-analysis including RCTs and NRCTs had the power to provide better inferences on an issue rarely examined in the context of a RCT. Second, we could not collect data on albumin and CRP levels, which are known as predictive factors for 30-day mortality after gastrostomy. [@B1] Furthermore, information on the use of prophylactic antibiotics could not be collected, as these could have introduced selection bias. However, we enrolled a comparative study with a higher quality to minimize these uninvestigated selection biases.

In conclusion, PEG was associated with a lower probability of 30-day mortality, suggesting that it could become the first choice for long-term enteral tube feeding. Further randomized prospective studies are needed to evaluate and compare the safety of gastrostomy tube insertion by the two different methods investigated in this study.
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###### Characteristics of Trials Included in the Meta-Analysis

![](ir-14-333-i001)

  Author (year)                          Country       Study type                    Quality score^a^   Underlying disease   Sample size   
  -------------------------------------- ------------- ----------------------------- ------------------ -------------------- ------------- -----
  Lewis et al. (2014)[@B16]              UK            Randomized controlled trial   3/5                Mixed                34            31
  Hoffer et al. (1999)**[@B39]**         USA           Randomized controlled trial   2/5                Mixed                69            66
  ProGas Study Group (2015)[@B9]         UK            Prospective                   22/24              MND                  157           114
  Laskaratos et al. (2013)[@B8]          UK            Retrospective                 20/24              Mixed                53            40
  Allen et al. (2013)[@B19]              USA           Retrospective                 14/24              MND                  57            51
  La Nauze et al. (2012)[@B20]           Australia     Retrospective                 18/24              Mixed                80            97
  Rio et al. (2010)[@B22]                UK            Retrospective                 17/24              MND                  21            121
  Leeds et al. (2010)[@B23]              UK            Prospective                   22/24              Mixed                233           170
  Blondet et al. (2010)[@B24]            France        Retrospective                 18/24              MND                  21            22
  Galaski et al. (2009)[@B26]            Canada        Retrospective                 20/24              Mixed                30            44
  Eze et al. (2007)[@B28]                UK            Retrospective                 17/24              H&N                  44            15
  Silas et al. (2005)[@B31]              USA           Retrospective                 18/24              Mixed                177           193
  Desport et al. (2005)[@B32]            France        Prospective                   19/24              MND                  30            20
  Neeff et al. (2003)[@B33]              New Zealand   Retrospective                 17/24              H&N                  56            18
  Wollman and D\'Agostino (1997)[@B42]   USA           Retrospective                 20/24              Mixed                79            46

^a^Jadad score for randomized controlled trials, methodological index for nonrandomized studies (MINORS) score for nonrandomized comparative studies.

PEG, percutaneous endoscopic gastrostomy; RIG, radiologically-inserted gastrostomy; MND, motor neuron disease; H&N, head and neck cancer.

###### Indications for Gastrostomy

![](ir-14-333-i002)

  Author                          H&N       Neurological impairment^a^   Others    Total                               
  ------------------------------- --------- ---------------------------- --------- --------- --------- --------- ----- -----
  Lewis et al.[@B16]              4         7                            20        20        4         1         34    31
  Hoffer et al.[@B39]             7         9                            54        55        8         2         69    66
  ProGas Study Group[@B9]         0         0                            157       114       0         0         157   114
  Laskaratos et al.[@B8]          8         9                            34        21        11        10        53    40
  Allen et al.[@B19]              0         0                            57        51        0         0         57    51
  La Nauze et al.[@B20]           16        31                           48        54        15        16        80    97
  Rio et al.[@B22]                0         0                            21        121       0         0         21    121
  Leeds et al.[@B23]              69        106                          111       46        53        18        233   170
  Blondet et al.[@B24]            0         0                            21        22        0         0         21    22
  Galaski et al.[@B26]            Unknown   Unknown                      Unknown   Unknown   Unknown   Unknown   30    44
  Eze et al.[@B28]                44        15                           0         0         0         0         44    15
  Silas et al.[@B31]              41        0134                         89        37        47        22        177   193
  Desport et al.[@B32]            0         0                            30        20        0         0         30    20
  Neeff et al.[@B33]              56        18                           0         0         0         0         56    18
  Wollman and D\'Agostino[@B42]   13        25                           84        25        17        18        79    46

^a^Neurological impairment includes motor neuron disease, cerebrovascular disease, cerebral tumor, and cerebral trauma.

H&N, head and neck cancer; PEG, percutaneous endoscopic gastrostomy; RIG, radiologically-inserted gastrostomy.

###### Thirty-Day Mortality Rate

![](ir-14-333-i003)

  Author                          30-Day mortality   
  ------------------------------- ------------------ --------
  Lewis et al.[@B16]              2/34               2/31
  Hoffer et al.[@B39]             5/69               4/66
  ProGas Study Group[@B9]         5/163              4/121
  Laskaratos et al.[@B8]          6/53               14/40
  Allen et al.[@B19]              4/57               6/51
  La Nauze et al.[@B20]           3/80               5/97
  Rio et al.[@B22]                2/21               12/121
  Leeds et al.[@B23]              25/233             26/170
  Blondet et al.[@B24]            2/21               2/22
  Galaski et al.[@B26]            1/30               8/44
  Eze et al.[@B28]                1/44               5/15
  Silas et al.[@B31]              8/177              6/193
  Desport et al.[@B32]            4/30               2/20
  Neeff et al.[@B33]              3/56               6/18
  Wollman and D\'Agostino[@B42]   8/79               4/46

PEG, percutaneous endoscopic gastrostomy; RIG, radiologically-inserted gastrostomy.

[^1]: ^\*^These authors contributed equally to this study.
